Another biotech buy for Roche

After making a $43.7 billion offer linkurl:yesterday;http://www.the-scientist.com/blog/display/54841/ (July 21) to buy the 44% of Genentech stock it didn't already own, the Swiss pharmaceutical company announced another biotech purchase today. Roche will acquire linkurl:Mirus Bio Corporation;http://www.mirusbio.com/ for $125 million. Roche's half-year financial linkurl:results,;http://www.roche.com/home/figures/fig_halfyearrep_2008.htm released on Monday but eclipsed by the Genentech offer, showed a six percent decline in pharmaceutical sales. Roche intends to borrow half the funds required for the Genentech takeover, according to a report published Monday by Global Insight pharmaceutical analyst Gaelle Marinoni, which "implies that the Swiss giant is keeping its options and cash stash open for further smaller acquisitions." Mirus, one of those smaller acquisitions, is a private US-owned company based in Madison, Wisconsin that specializes in RNA interference (RNAi) technologies. Their products include nucleic acid reagents, kits, and protocols, and the company has siRNA delivery platforms in the pipeline. This is not Roche's first move toward linkurl:RNAi;http://www.the-scientist.com/article/display/18847/ therapeutics: last year, Roche struck a deal linkurl:Alnylam Pharmaceuticals Inc.,;http://www.the-scientist.com/blog/display/54395/ a German company, for the rights to their RNAi technology, an alliance the companies claimed to be worth $1 billion. "The race is on" for successful use of the RNAi technology, according to a Global Insight analysis, "and any breakthrough could prove very lucrative." Roche plans to maintain Mirus's research station in Madison. The takeover is scheduled to be completed by the end of the year. Meanwhile, Genentech and Roche leaders met today to informally discuss the buyout, but some analysts are expecting that Roche will to have to increase its offer to take over the biotech giant. The offer is at $89 a share, but Genentech stock jumped to $92.91 by the end of the day on Monday, a possible sign that investors expect a raise on the offer, according to linkurl:the Associated Press.;http://www.iht.com/articles/ap/2008/07/22/business/EU-Switzerland-Roche-Genentech.php

Another biotech buy for Roche

The Scientist ARCHIVES

Become a Member of

Meet the Author

Megan Scudellari

Related Research Resources

Study Confirms Safety of Genetically Modified T Cells

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

TaqMan Probe & Assays: Unveil What's Possible Together

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Making Real-Time PCR More Straightforward

Products

Product News

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

Agilent BioTek Cytation C10 Confocal Imaging Reader